Stem Cell Clinic

Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis

By Global News Feed

VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of psoriasis. Psoriasis is a chronic inflammatory skin disease often linked to depression and a decreased quality of life. The global psoriasis treatment market is projected to reach USD $37 billion by 2026. These results come on the heels of a successful preclinical study in atopic dermatitis earlier this year using the same drug.

Read more from the original source:
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis

Rafarma Approves Issuance of Majority of Voting Shares to Board Chairman Ilya Shpurov

By Global News Feed

Ljubljana, Slovenia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce approval of Ilya Shpurov receiving the majority of Preferred B shares, conferring voting control of the company, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group of Companies. The issuance of restricted preferred shares does not create any dilution of common shares.

See the original post here:
Rafarma Approves Issuance of Majority of Voting Shares to Board Chairman Ilya Shpurov

Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch…

By Global News Feed

·BYFAVO expected to be commercially available in the US before the end of the year             This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

See the article here:
Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch...

Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock

By Global News Feed

WESTLAKE VILLAGE, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the closing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $25.00 per share, before underwriting discounts and commissions. All of the shares in the public offering were sold by Arcutis. The gross proceeds from the public offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Arcutis, were $100.0 million. In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of Arcutis’ common stock at the public offering price less the underwriting discounts and commissions.

View post:
Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock

→←